PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 25 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
E. wushanense and E. koreanum showed similar pharmacological effects on KYD syndrome in hydrocortisone-induced rats, specifically regarding the secretion of testosterone [PMID:37774896]
The flavonoid wushanicaritin exhibited antioxidant activity comparable to Vitamin C in DPPH radical scavenging tests [PMID:21968061]
Diphylloside A, icarisoside A, and desmethylanhydroicaritin showed significant antibacterial activity against Pseudomonas aeruginosa [PMID:17613817]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 36120133 (2022) — Taxonomy of Epimedium (Berberidaceae) with special reference to Chinese species. · Chinese herbal medicines
- 2.PMID: 31426439 (2019) — Development of Plastid Genomic Resources for Discrimination and Classification of Epimedium wushanense (Berberidaceae). · International journal of molecular sciences
- 3.PMID: 33366765 (2020) — The complete chloroplast genome of Epimedium wushanense T. S. Ying. (Berberidaceae), a traditional Chinese medicinal herb. · Mitochondrial DNA. Part B, Resources
- 4.PMID: 38192750 (2024) — Production of Rhamnosyl Icariside II by snailase hydrolysis of Epimedium wushanense extracts. · Heliyon
- 5.PMID: 36740574 (2023)